Glioblastoma, the most aggressive high-grade glioma, is a devastating primary brain tumor resistant to conventional therapies, and the second most common cause of death from intracranial disease.
Approximately 25,000 patients are diagnosed in the United States and Europe with glioblastoma each year. After initial treatment with surgery, radiation, and chemotherapy, few options are available for patients who experience tumor progression. Many therapies targeting specific molecular pathways, even when used in combination, have failed to improve overall survival. Thus, it’s critical that novel drugs are developed that have a positive impact on the course of this aggressive disease.
To address this critical medical need, DNAtrix has developed DNX-2401, which offers a new mode of attack for treating patients with glioblastoma.
DNX-2401 + Pembrolizumab
Study 2401BT-002P (CAPTIVE) is a Phase 2 trial being conducted in collaboration with Merck to evaluate the efficacy and safety of DNX-2401 in combination with pembrolizumab (KEYTRUDA), Merck’s anti-PD-1 therapy. Adult subjects diagnosed with glioblastoma or gliosarcoma that have experienced disease progression after initial treatment may be eligible.
DNX-2401 for Pediatric Patients with Newly Diagnosed Pontine Glioma
Study D24-DIPG is a Phase 1 trial to evaluate the safety and efficacy of DNX-2401 in pediatric patients. Patients who are less than 18 years old with newly diagnosed diffuse intrinsic pontine glioma may be eligible.
Expanded Access/Compassionate Use:
At this time, DNAtrix does not offer expanded access or compassionate use programs for investigational agents under development. We evaluate the need on a continuous basis.